Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 25Leukemia, Myeloid, Acute 24Lymphoma 22Breast Neoplasms 20Prostatic Neoplasms 15Colorectal Neoplasms 15Melanoma 14Leukemia, Lymphocytic, Chronic, B-Cell 14Lung Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Neoplasm Metastasis 12Myelodysplastic Syndromes 12Lymphoma, Large B-Cell, Diffuse 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 11Ovarian Neoplasms 10Myeloproliferative Disorders 10Triple Negative Breast Neoplasms 8Rectal Neoplasms 8Leukemia, Myelomonocytic, Chronic 8Carcinoma, Renal Cell 8Burkitt Lymphoma 8Sarcoma 7Lymphoma, Follicular 7Colonic Neoplasms 7Urinary Bladder Neoplasms 6Lymphoma, Non-Hodgkin 6Glioma 6Fallopian Tube Neoplasms 6Cholangiocarcinoma 6

Interventions

Erlotinib Hydrochloride 2Bevacizumab 2pamiparib 1atezolizumab 1Temozolomide 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Contrast Media 1Botulinum Toxins, Type A 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hereditary leiomyomatosis and renal cell cancer × Biopsy × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡